Although antimicrobial agents are not indicated for uncomplicated *Salmonella* infections, fluoroquinolones and extended-spectrum cephalosporins are potentially life-saving treatments for extraintestinal infections ([@R1]). The National Antimicrobial Resistance Monitoring System (NARMS) has monitored antimicrobial drug resistance among enteric pathogens since 1996. NARMS has documented decreased susceptibility to each of these drug classes, in most instances among separate serotypes ([@R2]). Historically, decreased susceptibility to fluoroquinolones, which can be monitored by tracking resistance to nalidixic acid, has been noted among *Salmonella* serotypes (ser.) Typhi, Senftenberg, and Virchow ([@R2],[@R3]). More recently, decreased susceptibility to fluoroquinolones has been noted among *Salmonella* ser. Enteritidis ([@R4]). Decreased fluoroquinolone susceptibility has also been seen among nalidixic acid--susceptible isolates ([@R5]). Extended-spectrum cephalosporin resistance was noted among 15 non-Typhi *Salmonella* NARMS isolates (including 12 ser. Typhimurium) during 1996--1998 ([@R6]). In all instances, extended-spectrum cephalosporin resistance was the result of *bla*~CMY-2~, a class C plasmid-encoded *ampC* gene ([@R7]). In addition to conferring resistance or decreased susceptibility to extended-spectrum cephalosporins such as ceftiofur and ceftriaxone, this gene also confers resistance to ampicillin (AMP), amoxillin-clavulanate, cephalothin, and cefoxitin. This AmpC resistance phenotype has been seen in strains of *Salmonella* ser. Newport along with resistance to other drugs including chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. This MDRAmpC strain rose from 1% (1/77) of *Salmonella* ser. Newport submissions in 1998 to 25% (31/124) in 2001 ([@R4]). CMY β-lactamases are largely responsible for extended-spectrum cephalosporin resistance among *Salmonella* ser. Newport, Typhimurium, and others isolated in North America ([@R6],[@R8]).

Coresistance to fluoroquinolones and extended-spectrum cephalosporins would limit therapeutic options for *Salmonella* infections. Decreased susceptibility to both drug classes was identified in Thailand in 1993 (ser. Anatum, Derby, Enteritidis, Typhimurium, Weltevreden, and I 4,5,12:i:-) ([@R9]), the United Kingdom in 1998 (ser. Senftenberg, Typhimurium, and Virchow) ([@R10]), Belgium as early as 2001 (ser. Virchow) ([@R11]), India in 2002 (ser. Typhi) ([@R12]), the United States in 2002 (ser. Mbandaka) ([@R13]), France in 2003 ([@R11]), and Taiwan in 2004 (ser. Choleraesuis, Cairo, and Kaduna) ([@R14]). In the United States, 27 (4.6%) of 588 *Salmonella* ser*.* Typhimurium isolates (clinical and slaughter) obtained from food animals in 1999 were resistant to ceftiofur and nalidixic acid: 22 (81%) from turkeys, 4 (15%) from horses, and 1 (4%) from cattle ([@R15]).

To understand coresistance to both antimicrobial classes among *Salmonella* isolates obtained from humans in the United States, we studied the NARMS human collection from 1996 through 2004, looking for decreased susceptibility to quinolones and extended-spectrum cephalosporins. Information for some of the isolates has been presented elsewhere ([@R3],[@R13],[@R16]--[@R18]). We present the molecular epidemiology of this phenotype and mechanisms responsible for its decreased susceptibility.

Materials and Methods
=====================

Isolates and Antimicrobial Drug Susceptibility Testing
------------------------------------------------------

NARMS-participating state and local public health laboratories submitted non-Typhi *Salmonella* isolates to the Centers for Disease Control and Prevention (CDC) for antimicrobial susceptibility testing: every 10th isolate from 1996 through 2002 and every 20th isolate from 2003 to present. Serotypes were determined by the submitting laboratory and, for this study, were confirmed by the CDC National *Salmonella* Reference Laboratory according to the Kaufmann-White scheme as described ([@R19]). MICs were determined by using broth microdilution (Sensititre, Westlake, OH, USA). Isolates exhibiting an amikacin MIC \>4 μg/mL were confirmed by Etest (ABBiodisk, Piscataway, NJ, USA). Criteria for decreased susceptibility to quinolones and extended-spectrum cephalosporins were as follows: MIC [\>]{.ul}32 μg/mL for nalidixic acid or [\>]{.ul}0.12 μg/mL for ciprofloxacin and [\>]{.ul}2 μg/mL for ceftiofur or ceftriaxone. Susceptibility testing was performed according to manufacturer's instructions by using control strains *Escherichia coli* ATCC25922 and ATCC35218, and *Klebsiella pneumoniae* ATCC700603 (for extended-spectrum β-lactamase \[ESBL\] confirmation only). When available, Clinical Laboratory Standards Institute (CLSI) guidelines were used for interpretation ([@R20]).

Isoelectric Focusing for β-Lactamases
-------------------------------------

The methods of Rasheed et al. were used with modification ([@R21]). Three-hour trypticase soy broth cultures (grown at 37°C with shaking at 300 rpm) were pelleted, resuspended in 0.2% sodium acetate to 5% of original culture volume, and freeze-thawed 4 times (dry ice/ethanol bath and 37°C water bath). Preparations were diluted 2-fold with distilled water and swirled occasionally on ice for 30 min. Supernatants were collected after centrifugation (30 min at 20,200× *g*), and 3--5-µL aliquots were resolved for 1.5 h on Ampholine PAGplate polyacrylamide gels, pH 3.5--9.5 (APBiotech**,** Piscataway, NJ, USA). Gels were stained with nitrocefin (500 μg/mL; Becton Dickinson, Franklin Lakes, NJ, USA). Isoelectric points (pIs) were estimated by comparison with the following standard β-lactamases: TEM-12 (pI 5.25), KPC-2 (pI 6.7), SHV-3 (pI 7.0), SHV-18 (pI 7.8), and MIR-1 (pI 8.4).

PCR Detection of Antimicrobial Drug Resistance Genes
----------------------------------------------------

Presence of *qnr* genes was determined by using PCR with primers QP1 and QP2 for *qnrA* ([@R22]), FQ1 and FQ2 for *qnrB* ([@R23]), and 5′-ATGGAAACCTACAATCATAC-3′ and 5′-AAAAACACCTCGACTTAAGT-3′ for *qnrS*. The *qnrB* allele was determined by amplification and sequencing with primers FQ1 and FQ2. Screening for *aac(6′)-Ib-cr* was performed as described ([@R24]). Primer pairs used for amplification of β-lactamase genes were: *bla*~CMY~ (5′-ATGATGAAAAAATCGTTATGC-3′) and (5′-TTGCAGCTTTTCAAGAATGCGC-3′) ([@R25]); *bla*~OXA-1~ (5′-AATGGCACCAGATTCAACTT-3′) and 5′-CTTGGCTTTTATGCTTGATG-3′) ([@R26]); *bla*~TEM~ (5′-TTCTTGAAGACGAAAGGGC-3′) and (5′-ACGCTCAGTGGAACGAAAAC-3′) ([@R27]); and *bla*~SHV~ (5′-GGTTATGCGTTATATTCGCC-3′) and (5′-TTAGCGTTGCCAGTGCTC-3′) ([@R28]) or at Lahey (5′-GCCGGGTTATTCTTATTTGTC-3′) and (5′-TCTTTCCGATGCCGCCGCCAG-3′) ([@R29]). *bla*~CTX-M~ genes were screened by using a multiplex PCR assay ([@R30]).

DNA Sequencing
--------------

Full-length sequences were obtained for β-lactamase genes. A 255-bp region covering the quinolone-resistant determining region (QRDR) of *gyrA* (Met52 to Leu137) was amplified by using primers gyrA1: 5′-CATGAACGTATTGGGCAATG-3′ and gyrA2: 5′-AGATCGGCCATCAGTTCGTG-3′. QRDRs of *gyrB*, *parC*, and *parE* were amplified and sequenced by using previously described primers ([@R31]), except primers parCF (5′-ATCGTGCGTTGCCGTTTAT-3′) and parCR (5′-GCCGCTTTCGCCACTTC-3′) were used to enhance coverage of *parC*. Amplicons were sequenced by using ABI Big-Dye 3.1 chemistry and ABI 3730XL automated DNA sequencers (PE Biosystems, Foster City, CA, USA). Analysis was performed by using BioEdit ([www.mbio.ncsu.edu/BioEdit/bioedit.htmL](http://www.mbio.ncsu.edu/BioEdit/bioedit.htmL)) or SeqMan software (DNAStar, Madison, WI, USA). QRDR sequences of *gyrA*, *gyrB*, *parC*, and *parE* were compared with those of *Salmonella* ser*.* Typhimurium LT2 (GenBank accession nos. AE008801, AE008878, AE008846, and AE008846, respectively).

Pulsed-Field Gel Electrophoresis (PFGE)
---------------------------------------

PFGE was performed as previously described ([@R32]). Isolates that produced indistinguishable patterns with *Xba*I (Roche Molecular Biochemicals, Indianapolis, IN, USA) were restricted with *Bln*I. Patterns were analyzed by using the BioNumerics version 4.0 software (Applied Maths, Sint-Martens-Latem, Belgium) and compared by unweighted pair group method with averages by using the Dice coefficient with a 1.5% band position tolerance window. The DNA sequence and deduced amino acid sequence for the *Salmonella* ser. Senftenberg *bla*~CMY-23~ gene were assigned GenBank accession no. DQ463751.

Results
=======

Decreased susceptibility to quinolones and extended-spectrum cephalosporins was first noted in NARMS data in 1997 and represented 0.19% (27/14,043) of non-Typhi *Salmonella* from 1996 through 2004 ([Table 1](#T1){ref-type="table"}). *Salmonella* ser. Senftenberg was the most frequent serotype (n = 11), followed by Typhimurium (n = 6), Newport (n = 3), and Enteritidis (n = 2). The phenotype was found in 9 different serotypes ([Table 2](#T2){ref-type="table"}).

###### NARMS non-Typhi *Salmonella* serotypes with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996--2004\*

  Year    No. that met MIC criteria/total tested (%)   Serotype               
  ------- -------------------------------------------- ---------- --- --- --- ---------------------------
  1996    0/1,324 (0)                                                         
  1997    1/1,301 (0.08)                                          1           
  1998    1/1,460 (0.07)                                              1       
  1999    1/1,497 (0.07)                               1                      
  2000    4/1,377 (0.29)                               2          1       1   
  2001    4/1,419 (0.28)                               2          1           Haifa (1)
  2002    5/2,008 (0.25)                               1          2   1       Mbandaka (1)
  2003    4/1,864 (0.21)                               2                  1   Agona (1)
  2004    7/1,793 (0.39)                               3          1   1       Saintpaul (1), Uganda (1)
  Total   27/14,043 (0.19)                             11         6   3   2   5

\*NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as MIC [\>]{.ul}32 μg/mL for nalidixic acid or [\>]{.ul}0.12 μg/mL for ciprofloxacin and [\>]{.ul}2 μg/mL for ceftiofur or [\>]{.ul}2 μg/mL for ceftriaxone.

###### Isolate, year reported, state, and serotype for NARMS non-Typhi *Salmonella* isolates with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996--2004\*

  Isolate   Year   State   Serotype
  --------- ------ ------- -------------
  AM18280   2003   TX      Agona
  AM09124   2000   CA      Enteritidis
  AM15266   2003   IL      Enteritidis
  AM12389   2001   NJ      Haifa
  AM15010   2002   NY      Mbandaka
  AM03005   1998   NY      Newport
  AM15201   2002   ME      Newport
  AM21465   2004   GA      Newport
  AM20428   2004   GA      Saintpaul
  AM06960   1999   FL      Senftenberg
  AM08081   2000   FL      Senftenberg
  AM08208   2000   GA      Senftenberg
  AM09864   2001   FL      Senftenberg
  AM11007   2001   MA      Senftenberg
  AM14058   2002   TX      Senftenberg
  AM16094   2003   FL      Senftenberg
  AM18622   2003   FL      Senftenberg
  AM19422   2004   FL      Senftenberg
  AM20227   2004   GA      Senftenberg
  AM20256   2004   FL      Senftenberg
  AM02544   1997   MN      Typhimurium
  AM08739   2000   KS      Typhimurium
  AM11682   2001   NY      Typhimurium
  AM14364   2002   WI      Typhimurium
  AM14807   2002   NY      Typhimurium
  AM20205   2004   PA      Typhimurium
  AM19537   2004   CA      Uganda

\*NARMS, National Antimicrobial Resistance Monitoring System.

PFGE comparison by *Xba*I and, if applicable, *Bln*I restriction showed that 15/27 *Salmonella* isolates differed by [\>]{.ul}1 band. No indistinguishable patterns among different *Salmonella* serotypes were identified. Of the 3 ser. Newport isolates tested, 2 (AM15201 and AM21465) had indistinguishable *Xba*I patterns but different *Bln*I patterns (87.51% similarity). The 2 Enteritidis isolates (AM09124 and AM15266) were indistinguishable by both enzymes. Of the 11 ser. Senftenberg isolates, 5 exhibited unique *Xba*I PFGE patterns, while the remaining 6 were separated into 2 groups with indistinguishable *Xba*I PFGE patterns (group 1: AM06960, AM08081, AM16094, and AM19422; group 2: AM20227 and AM20256). *Bln*I restriction demonstrated that AM19422 differed from the other group 1 isolates by a single band difference (97.44% similarity). PFGE results for some of the Senftenberg isolates are described elsewhere ([@R16],[@R18]). All Typhimurium isolates exhibited unique *Xba*I PFGE patterns (77%--93% similarity).

Antimicrobial drug susceptibility results are presented in [Table 3](#T3){ref-type="table"}. For nalidixic acid, 25 isolates exhibited an MIC \>32 μg/mL, and 2 (Mbandaka and Newport) had an MIC of 16 μg/mL. For ciprofloxacin, MICs of 0.12--0.5 μg/mL were found for all isolates except the 11 Senftenberg, for which the MIC was \>4 μg/mL. For ceftiofur, 14 isolates exhibited resistance (MIC [\>]{.ul}8 μg/mL). For ceftriaxone, 2 isolates exhibited resistance according to the current CLSI breakpoint (64 μg/mL), and 7 exhibited intermediate resistance (MIC 16 or 32 μg/mL). Three isolates (Mbandaka, Senftenberg, and Typhimurium) exhibited an ESBL phenotype according to ceftazidime and cefotaxime MIC alone and with clavulanate. Seven isolates exhibited the MDRAmpC phenotype, including 1 Agona, 2 Newport, 3 Typhimurium, and 1 Uganda. According to current CLSI guidelines, 1 isolate (ser. Senftenberg) was fully resistant to ciprofloxacin, ceftriaxone, ceftazidime, and cefotaxime.

###### Susceptibility results for NARMS non-Typhi *Salmonella* isolates with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996--2004\*

  Isolate   Resistance                                                                  
  --------- ------------ ------ ------ --------------- ------ -------- ------ --------- -------------------------------------------------
  AM18280   \>32         0.25   \>8    16              32     16/4     16     8/4       AMP, AMC, CHL, FOX, KAN, STR, SUL, SXT, TET
  AM09124   \>32         0.5    2      [\<]{.ul}0.25   0.5    0.25/4   0.25   0.12/4    ND
  AM15266   \>32         0.5    2      [\<]{.ul}0.25   0.5    0.25/4   0.25   0.12/4    (CHL)
  AM12389   \>32         0.5    2      [\<]{.ul}0.25   0.25   0.25/4   0.1    0.12/4    (CHL), SUL, SXT, TET
  AM15010   16           0.25   8      8               64     0.5/4    4      0.25/4    AMP, (CHL), SUL, SXT
  AM03005   16           0.25   2      0.5             0.25   0.12/4   0.12   ≤0.06/4   AMP, AMC, CHL, FOX, (GEN), KAN, STR, SUL, SXT
  AM15201   \>32         0.12   \>8    8               16     16/4     16     8/4       AMP, AMC, CHL, FOX, STR, SUL, TET
  AM21465   \>32         0.12   \>8    16              16     16/4     8      8/4       AMP, AMC, CHL, FOX, STR, SUL, TET
  AM20428   \>32         0.5    2      [\<]{.ul}0.25   0.5    0.5/4    0.5    0.12/4    (CHL), (FOX)
  AM06960   \>32         \>4    8      8               0.5    0.25/4   1      0.12/4    AMP, AMC, (CHL), GEN, KAN, STR, SUL, SXT
  AM08081   \>32         \>4    4      0.5             0.5    0.25/4   1      0.12/4    AMP, AMC, CHL, FOX, (GEN), KAN, STR, SUL, SXT
  AM08208   \>32         \>4    2      [\<]{.ul}0.25   0.5    0.25/4   0.5    0.25/4    AMP, (AMC) CHL, GEN, KAN, STR, SUL, SXT, TET
  AM09864   \>32         \>4    8      8               64     0.25/4   8      0.25/4    AMP, (CHL), (FOX), GEN, KAN
  AM11007   \>32         \>4    4      0.5             1      0.5/4    1      0.5/4     AMP, AMC, CHL, (FOX), KAN, SUL
  AM14058   \>32         \>4    \>8    \>64            64     64/4     128    \>64/4    (AMI), AMP, AMC, CHL, FOX, KAN, SUL
  AM16094   \>32         \>4    4      [\<]{.ul}0.25   0.5    0.25/4   1      0.25/4    AMP, (AMC), CHL, (FOX), (GEN), KAN, SUL, SXT
  AM18622   \>32         \>4    8      1               2      0.5/4    4      0.5/4     AMP, AMC, CHL, KAN, STR, SUL, SXT
  AM19422   \>32         \>4    4      [\<]{.ul}0.25   0.5    0.5/4    2      0.25/4    AMP, AMC, (GEN), KAN, STR, SUL, SXT
  AM20227   \>32         \>4    2      [\<]{.ul}0.25   1      2/4      1      0.5/4     AMP, AMC, (CHL), (FOX), GEN, KAN, STR, SUL, SXT
  AM20256   \>32         \>4    4      [\<]{.ul}0.25   0.5    0.5/4    1      0.25/4    AMP, (AMC), (CHL), (GEN), KAN, SUL, SXT
  AM02544   256          0.25   \>16   64              128    0.5/4    32     0.12/4    AMP, (AMC), KAN, STR, SUL, TET
  AM08739   \>32         0.25   \>8    32              16     16/4     16     8/4       AMP, AMC, CHL, FOX, GEN, KAN, STR, SUL, TET
  AM11682   \>32         0.25   \>8    16              16     8/4      16     8/4       AMP, AMC, FOX
  AM14364   \>32         0.25   \>8    32              32     16/4     32     16/4      AMP, AMC, CHL, FOX, GEN, KAN, STR, SUL, TET
  AM14807   \>32         0.25   \>8    16              32     16/4     16     32/4      AMP, AMC, CHL, FOX, STR, SUL, TET
  AM20205   \>32         0.25   2      [\<]{.ul}0.25   0.5    0.5/4    0.25   0.25/4    AMP, KAN, STR, SUL, TET
  AM19537   \>32         0.12   \>8    16              16     16/4     8      8/4       AMP, AMC, CHL, FOX, (GEN), (KAN), STR, SUL TET

\*NARMS, National Antimicrobial Resistance Monitoring System; NAL, nalidixic acid; CIP, ciprofloxacin; XNL, ceftiofur; CRO, ceftriaxone; TAZ, ceftazidime; TAZ/CLAV, ceftazidime/clavulanate; FOT, cefotaxime, FOT/CLAV, cefotaxime/clavulanate; AMP, ampicillin; AMC, amoxicillin/clavulanate; CHL, chloramphenicol; FOX, cefoxitin; KAN, kanamycin; STR, streptomycin; SUL, sulfamethoxazole or sulfisoxazole; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; AMI, amikacin; GEN, gentamicin. †Drugs in parentheses had intermediate results.

The mechanisms responsible for resistance and decreased susceptibility are shown in [Table 4](#T4){ref-type="table"}. Some mechanisms for some of the isolates are presented elsewhere ([@R3],[@R17],[@R18]). At least 1 *gyrA* mutation was found in 26 of 27 isolates. A *gyrA* mutation at codon 83 only was found for 11 isolates; a mutation at codon 87 only was found for 3; mutations at both codons were found for 12. No functional mutations were detected in *gyrB* or *parE* genes. All Senftenberg isolates had *parC* mutations (S80I and T57S), and 6 other isolates had the T57S mutation. In addition to the T57S mutation in *parC*, the Mbandaka isolate contained a plasmid-mediated *qnrB2* gene and has been described ([@R13]). Four isolates contained *aac(6′)-Ib*, but none contained the ciprofloxacin-modifying *aac(6′)-Ib-cr* variant.

###### Resistance mechanisms among NARMS non-Typhi *Salmonella* with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996--2004\*

  Isolate   *gyrA* codon 83 change   *gyrA* codon 87 change   *parC* codon 57 change   *parC* codon 80 change   β-Lactamase isoelectric points   β-Lactamase genes
  --------- ------------------------ ------------------------ ------------------------ ------------------------ -------------------------------- -------------------------------------------
  AM18280   S83Y                     WT                       T57S                     WT                       [\>]{.ul}8.4                     *bla*~CMY-2~
  AM09124   S83F                     WT                       WT                       WT                       ND                               ND
  AM15266   WT                       D87Y                     WT                       WT                       ND                               ND
  AM12389   S83Y                     WT                       WT                       WT                       ND                               ND
  AM15010   WT                       WT                       T57S                     WT                       7.0, 7.6†                        *bla*~SHV-30~
  AM03005   S83Y                     D87G                     T57S                     WT                       ND                               ND
  AM15201   S83F                     WT                       T57S                     WT                       [\>]{.ul}8.4                     *bla*~CMY-2~
  AM21465   S83F                     WT                       T57S                     WT                       [\>]{.ul}8.4                     *bla*~CMY-2~
  AM20428   S83F                     WT                       WT                       WT                       5.4                              *bla*~TEM-1b~
  AM06960   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM08081   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM08208   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM09864   S83Y                     D87G                     T57S                     S80I                     5.3, 6.9, 8.0                    *bla*~TEM-1~, *bla*~OXA-9~, *bla*~SHV-12~
  AM11007   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM14058   S83Y                     D87G                     T57S                     S80I                     5.4, [\>]{.ul}8.4                *bla*~TEM-1b~, *bla*~CMY-23~
  AM16094   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM18622   S83Y                     D87G                     T57S                     S80I                     7.4, 7.8                         *bla*~OXA-1~
  AM19422   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM20227   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM20256   S83Y                     D87G                     T57S                     S80I                     7.4                              *bla*~OXA-1~
  AM02544   WT                       D87N                     WT                       WT                       5.4, 8.0                         *bla*~TEM-1~, *bla*~OXA-1~, *bla*~SHV-12~
  AM08739   S83Y                     WT                       WT                       WT                       5.4, [\>]{.ul}8.4                *bla*~TEM-1b~, *bla*~CMY-2~
  AM11682   S83F                     WT                       WT                       WT                       [\>]{.ul}8.4                     *bla*~CMY-2~
  AM14364   S83Y                     WT                       WT                       WT                       5.4, [\>]{.ul}8.4                *bla*~TEM-1b~, *bla*~CMY-2~
  AM14807   S83Y                     WT                       WT                       WT                       [\>]{.ul}8.4                     *bla*~CMY-2~
  AM20205   WT                       D87N                     WT                       WT                       5.4                              *bla*~TEM-1b~
  AM19537   S83Y                     WT                       T57S                     WT                       [\>]{.ul}8.4                     *bla*~CMY-2~

\*NARMS, National Antimicrobial Resistance Monitoring System; WT, wild type; ND, not determined. †Gene responsible not yet identified.

Nine AmpC phenotype isolates produced β-lactamase with a pI [\>]{.ul}8.4 ([Table 4](#T4){ref-type="table"}); 8 contained *bla*~CMY-2~, but the Senftenberg strain contained a *bla*~CMY-23~ gene (GenBank accession no. DQ463751) identical to that found in an *E. coli* isolate (GenBank accession no. DQ438952). This gene differs from *bla*~CMY-2~ by 1 amino acid. Three of the *bla*~CMY~-positive isolates, including the strain positive for *bla*~CMY-23~, also contained *bla*~TEM-1b~. The Mbandaka isolate was positive for *bla*~SHV-30~ with pI 7.0 ([@R33]) and also produced an enzyme with a pI 7.6, the nature of which is still under study. Two isolates (1 Senftenberg and 1 Typhimurium) contained *bla*~SHV-12~, and both also contained *bla*~OXA~ and *bla*~TEM-1~ genes. Of the 11 Senftenberg isolates, 10 contained *bla*~OXA-1~ (n = 9) or *bla*~OXA-9~ (n = 1). No isolates contained *bla*~CTX-M~ genes.

Discussion
==========

Fluoroquinolone and extended-spectrum cephalosporin coresistance is rare; however, the appearance of this phenotype in 2 commonly isolated serotypes from humans (Typhimurium and Newport) is concerning. Sporadic infections are alarming, but if clonal expansion of an isolate with this phenotype were to take place, as occurred with *Salmonella* ser. Typhimurium DT104 and Newport-MDRAmpC, the clinical consequences could be dramatic. Statistically significant increases in resistance to nalidixic acid (odds ratio \[OR\] 6.7, 95% confidence interval \[CI\] CI 2.6--17.7) and ceftiofur (OR 43.2, 95% CI 10.5--177.4) have been documented among non-Typhi *Salmonella* of human origin submitted to NARMS during 1996--2003 ([@R4]). Of 202 nalidixic acid--resistant non-Typhi *Salmonella* collected by NARMS during 1996--2003, most were ser. Enteritidis (31%) or Typhimurium (10%). Most of the 324 ceftiofur-resistant non-Typhi *Salmonella* collected by NARMS during the same time period were ser. Newport (56%) or Typhimurium (23%). A slightly broader geographic representation can be found in the SENTRY surveillance project, which analyzed 786 *Salmonella* isolates (blood and stool) from medical facilities in Latin America and North America (including Canada) during 2001--2003 ([@R8]). Of these, 11% were resistant to nalidixic acid, and 2% exhibited decreased susceptibility to ceftazidime, ceftriaxone, or aztreonam.

Extended-spectrum cephalosporin-resistant Newport and Typhimurium isolates are typically obtained from community-acquired infections. Newport-MDRAmpC infections have been associated with consumption of contaminated beef and unpasteurized dairy products ([@R34]). *Salmonella* containing *bla*~CMY~ genes have been isolated from ground chicken (Typhimurium DT208), turkey (Agona), and beef (Agona) purchased from retail outlets in the Washington DC area ([@R35]). In addition, cattle, chickens, turkeys, pigs, horses, and dogs have all been sources of *bla*~CMY~-containing *Salmonella,* including common serotypes such as Typhimurium, Newport, and Heidelberg ([@R26],[@R36],[@R37]). Decreased susceptibility to fluoroquinolones among *Salmonella* serotypes that typically carry *bla*~CMY~ genes warrants exploration of factors that could select for decreased susceptibility to fluoroquinolones in animal reservoirs and in the human host.

PFGE showed diversity within some serotypes and indistinguishable strains within others. PFGE diversity among 2 serotypes commonly associated with extended-spectrum cephalosporin resistance (Newport and Typhimurium) is not surprising, given that CMY-producing strains have been seen at least since the late 1990s. Isolates of ser. Enteritidis are highly clonal; therefore, PFGE-indistinguishable patterns among isolates with no apparent epidemiologic link are not unusual. All PFGE-indistinguishable Senftenberg isolates from group 1 were isolated in the same state. Results for the Florida Senftenberg isolates are described elsewhere ([@R16],[@R18]).

*Salmonella* ser. Senftenberg exhibiting decreased susceptibility to fluoroquinolones has been associated with nosocomial infections in healthcare facilities in the United States ([@R18]). All 11 isolates contained identical *gyrA* mutations (S83Y and D87G) and *parC* mutations (T57S and S80I). These *parC* mutations have been identified in several *Salmonella* serotypes including Senftenberg ([@R38]). Ten Senftenberg isolates included in this study contained *bla*~OXA~ genes; the *bla*~OXA~-negative Senftenberg strain contained a *bla*~CMY-23~ mechanism of extended-spectrum cephalosporin resistance. Acquisition of a *bla*~CMY~ gene by a traditionally nalidixic acid--resistant serotype warrants further epidemiologic and laboratory investigation. The *bla*~OXA-1~ gene has been identified in *Salmonella* ser. Typhimurium and is reported to be carried by an integron ([@R39]); *bla*~OXA-9~ has been associated with Tn1331 ([@R40]).

The epidemiology of *Salmonella* with decreased susceptibility to fluoroquinolones is relatively well characterized, as is that of *Salmonella* with *bla*~CMY~-mediated extended-spectrum cephalosporin resistance. Conversely, little is known about the events leading to quinolone and extended-spectrum cephalosporin coresistance and the epidemiology of these infections in humans. Patients with *Salmonella* infections who exhibit decreased susceptibility to both antimicrobial drug classes should be interviewed to determine risk factors and the effects of antimicrobial drugs and other potential selective factors on this phenomenon.
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